Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BeiGene Ltd ( (HK:6160) ) just unveiled an announcement.
BeOne Medicines Ltd., a Swiss corporation, has announced a significant financial transaction involving the sale of royalty rights related to its monoclonal antibody product, Imdelltra, to Royalty Pharma Investments 2023 ICAV. The agreement involves an upfront payment of $885 million for a portion of the royalty rights, with an option for additional sales up to $65 million. This transaction is expected to have a material financial impact on BeOne’s operations, enhancing its financial position and potentially influencing its industry standing.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,394,131
Technical Sentiment Signal: Buy
Current Market Cap: HK$298B
See more insights into 6160 stock on TipRanks’ Stock Analysis page.